Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.BrainsWay.com. Contacts: BrainsWay: Scott Areglado SVP and Chief Financial Officer 844-386-7001 Scott.Areglado@BrainsWay.com Investors: Bob Yedid LifeSci Advisors 646-597-6989 Bob@LifeSciAdvisors.com Source: BrainsWay 2022 GlobeNewswire, Inc., source Press Releases